Medtronic Touts Drug-coated Balloon Data in Toughest Peripheral Artery Disease Cases

Tuesday, April 26, 2016

Source: FierceMedicalDevices

Medtronic ($MDT) has unveiled two-year data for a drug-coated balloon to treat peripheral artery disease (PAD) that shows it can be effective in patient populations that are typically not good responders to balloon angioplasty: women and diabetics.

The trial for the IN.PACT Admiral, which has a paclitaxel coating for a sustained anti-restenotic effect, found that women and diabetics had a higher primary patency rate and a lower rate of lesion revascularization than with traditional balloon angioplasty.

"The IN.PACT Admiral drug-coated balloon's unique coating delivers paclitaxel in a solid state which results in durable tissue levels of drug leading to prolonged anti-restenotic effect. We have first-of-its-kind data that shows it continues to do so even in the more challenging cases and patient populations," said principal investigator Dr. Peter Schneider of Kaiser Medical Center in Honolulu, HI, in a statement. "These data continue to position the IN.PACT Admiral drug-coated balloon as a durable treatment option for femoropopliteal interventions."

View All News »